MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as GBX 210.36 ($2.71) and last traded at GBX 226.90 ($2.92), with a volume of 64798 shares. The stock had previously closed at GBX 230 ($2.96).
MaxCyte Trading Down 1.3 %
The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The company has a market cap of £299.52 million, a price-to-earnings ratio of -8.31 and a beta of 1.13. The firm has a 50-day moving average price of GBX 312.21 and a 200 day moving average price of GBX 305.38.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Further Reading
- Five stocks we like better than MaxCyte
- Why Invest in High-Yield Dividend Stocks?
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- How Technical Indicators Can Help You Find Oversold Stocks
- Top 3 Beverage Stocks Pouring Out Profits
- 10 Best Airline Stocks to Buy
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
